Methimazole-Associated Neutropenia and Agranulocytosis in Pediatric Patients with Graves’ Disease: A Chinese Cohort Study
Authors' conclusion
Pediatric patients with GD younger than 3 years with TPOAb-negative status or a baseline ANC < 3 × 109/L may have a higher prevalence of MMI-associated neutropenia.
Study context
- Population
- Pediatric patients with graves' disease (GD) treated with MMI, China
- Participants
- 432 patients
- Outcome
- MMI-associated neutropenia and agranulocytosis
- Follow-up
- 12-month follow-up
Methodological detailsretrospective and prospective data collection, multivariable logistic regression
- Retrospective and prospective data collection
- Multivariable logistic regression
Main finding
As reported in the abstract
MMI-associated neutropenia
- Developed neutropenia
- 104 (24.1%)
- Neutropenia within first 3 months
- 84.6%
- Neutropenia within 1 month
- 72.1%
- Neutropenia within 2 weeks
- 59.6%
- Mild neutropenia among affected
- 83.7%
- Moderate neutropenia among affected
- 13.5%
- Severe neutropenia (agranulocytosis) among affected
- 2.8%
Observational data: associations, not effects.
Further findings
Risk factors for MMI-associated neutropenia (multivariable analysis)
| OR (CI) | ||
|---|---|---|
| TPOAb-negative statusHigher prevalence | 2.020 (1.113–3.666) | |
| Older ageProtective | 0.916 (0.848–0.989) | |
| Higher baseline ANCProtective | 0.775 (0.665–0.903) | |
| 0.20.5125Odds ratio (log scale) |
Original publication
Methimazole-Associated Neutropenia and Agranulocytosis in Pediatric Patients with Graves’ Disease: A Chinese Cohort Study. Thyroid. Published 21 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →